This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-outlook: Archive
EOG Resources (EOG) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
EOG Resources (EOG) delivered earnings and revenue surprises of +4.98% and +0.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
EOGNegative Net Change NFENegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
HireQuest, Inc. (HQI) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
HireQuest (HQI) delivered earnings and revenue surprises of +36.36% and +1.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
HQIPositive Net Change DSPNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Maplebear (CART) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Maplebear (CART) delivered earnings and revenue surprises of +5.13% and +2.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CARTPositive Net Change PSQHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -2.33% and -84.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DNTHPositive Net Change CVACNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
GigaCloud Technology Inc. (GCT) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
GigaCloud Technology Inc. (GCT) delivered earnings and revenue surprises of +97.83% and +11.17%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
GCTPositive Net Change BTBTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
GoDaddy (GDDY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
GoDaddy (GDDY) delivered earnings and revenue surprises of +5.22% and +1.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
GDDYPositive Net Change VRNTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Akamai Technologies (AKAM) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Akamai Technologies (AKAM) delivered earnings and revenue surprises of +11.61% and +2.17%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
AKAMPositive Net Change LPSNPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix (BDSX) delivered earnings and revenue surprises of -14.29% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BDSXNegative Net Change HQYPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
BioLife Solutions, Inc. (BLFS) Reports Break-Even Earnings for Q2
by Zacks Equity Research
BioLife Solutions (BLFS) delivered earnings and revenue surprises of +100.00% and +6.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BLFSNegative Net Change ALURNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of +19.72% and +2.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
AMPHNegative Net Change TSHANo Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Clipper Realty Inc. (CLPR) Beats Q2 FFO Estimates
by Zacks Equity Research
Clipper Realty (CLPR) delivered FFO and revenue surprises of +33.33% and -0.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CLPRNegative Net Change SOHONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Expedia (EXPE) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Expedia (EXPE) delivered earnings and revenue surprises of +2.42% and +1.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
EXPEPositive Net Change CHWYPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Texas Roadhouse (TXRH) Lags Q2 Earnings Estimates
by Zacks Equity Research
Texas Roadhouse (TXRH) delivered earnings and revenue surprises of -4.62% and +0.55%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
TXRHNegative Net Change CAVAPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Ascend Wellness Holdings, Inc. (AAWH) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ascend Wellness Holdings, Inc. (AAWH) delivered earnings and revenue surprises of -71.43% and -0.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
AAWHPositive Net Change PINCPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
IOVAPositive Net Change RNAPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
The Trade Desk (TTD) Lags Q2 Earnings Estimates
by Zacks Equity Research
The Trade Desk (TTD) delivered earnings and revenue surprises of -2.38% and +1.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
TTDPositive Net Change MCHXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcellx (ACLX) delivered earnings and revenue surprises of +8.74% and -54.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ACLXPositive Net Change GYRENegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of +16.42% and +1,658.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CYTKNegative Net Change STROPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +16.67% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DVAXPositive Net Change IMTXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Is CVS a Smart Buy Now on Strong Q2, Low Valuation & Long-Term Upside?
by Urmimala Biswas
CVS appears well-poised on strong Q2 revenue growth, raised full-year guidance and momentum in key healthcare segments.
UNHPositive Net Change CVSPositive Net Change HLFPositive Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-surprise healthcare medical medical-devices
Epam (EPAM) Beats Q2 Earnings Estimates (Revised)
by Zacks Equity Research
Epam (EPAM) delivered earnings and revenue surprises of 6.13% and +1.53%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
EPAMNegative Net Change AINegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Lincoln Electric (LECO) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Lincoln Electric (LECO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
LECONegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Groupon (GRPN) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Groupon (GRPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
GRPNNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
New Jersey Resources (NJR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
New Jersey Resources (NJR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NJRNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
TrueBlue (TBI) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
TrueBlue (TBI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TBINegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank